The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
出版年份 2018 全文链接
标题
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
作者
关键词
-
出版物
ONCOGENE
Volume 37, Issue 20, Pages 2687-2701
出版商
Springer Nature
发表日期
2018-02-27
DOI
10.1038/s41388-018-0150-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- Is a super-enhancer greater than the sum of its parts?
- (2017) Noah Dukler et al. NATURE GENETICS
- Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
- (2017) Natalia Moreno et al. Oncotarget
- CDK9-dependent RNA polymerase II pausing controls transcription initiation
- (2017) Saskia Gressel et al. eLife
- BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
- (2016) Yuhki Yokoyama et al. CANCER RESEARCH
- A Landscape of Pharmacogenomic Interactions in Cancer
- (2016) Francesco Iorio et al. CELL
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models
- (2016) Caroline Berenguer-Daizé et al. INTERNATIONAL JOURNAL OF CANCER
- HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
- (2016) Xiaoyu Lin et al. MOLECULAR CANCER THERAPEUTICS
- A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
- (2016) I. C. Waizenegger et al. MOLECULAR CANCER THERAPEUTICS
- Heptad-Specific Phosphorylation of RNA Polymerase II CTD
- (2016) Roland Schüller et al. MOLECULAR CELL
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire
- (2016) Zeynab Najafova et al. NUCLEIC ACIDS RESEARCH
- BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells
- (2016) S V Muralidharan et al. ONCOGENE
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
- (2015) A. Henssen et al. CLINICAL CANCER RESEARCH
- Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models
- (2015) Ye Sol Lee et al. MOLECULAR CANCER THERAPEUTICS
- BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
- (2015) Jae-Seok Roe et al. MOLECULAR CELL
- Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
- (2015) Denes Hnisz et al. MOLECULAR CELL
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- What are super-enhancers?
- (2015) Sebastian Pott et al. NATURE GENETICS
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Getting up to speed with transcription elongation by RNA polymerase II
- (2015) Iris Jonkers et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
- (2015) Matthew B. Siegel et al. Oncotarget
- BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
- (2015) Marie-Magdelaine Coudé et al. Oncotarget
- Abstract 3686: HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells
- (2015) Santhana G. T. Devaraj et al. CANCER RESEARCH
- Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
- (2015) Harald Herrmann et al. Oncotarget
- Targeting the histone orthography of cancer: drugs for writers, erasers and readers
- (2014) Laia Simó-Riudalbas et al. BRITISH JOURNAL OF PHARMACOLOGY
- Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein (snRNP) Activates Hexamethylene Bisacetamide-inducible Protein (HEXIM1) Transcription
- (2014) Pingyang Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
- (2014) Tomohiko Kanno et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
- (2013) Warren A. Whyte et al. CELL
- Super-Enhancers in the Control of Cell Identity and Disease
- (2013) Denes Hnisz et al. CELL
- Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
- (2013) Wen Liu et al. CELL
- BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response
- (2013) Kristopher A. Sarosiek et al. MOLECULAR CELL
- Bromodomain-containing Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells
- (2012) Weishi Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein
- (2012) Koen Bartholomeeusen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- The multi-tasking P-TEFb complex
- (2008) Vanessa Brès et al. CURRENT OPINION IN CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now